BURRELL INTERNATIONAL GROUP LLC for EMERGENT BIOSOLUTIONS INC (F/K/A ADAPT PHARMA INC )
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
House and Senate Opioid Packages: H.R.6 - 115th Congress (2017-2018) SUPPORT for Patients and Communities Act; S.3120 - 115th Congress (2017-2018) HEAL Act of 2018; H.R.5925 - 115th Congress (2017-2018) CRISIS Act; H.R.5590 - 115th Congress (2017-2018) Opioid Addiction Action Plan Act; H.R.5774 - 115th Congress (2017-2018) Combating Opioid Abuse for Care in Hospitals Act of 2018; Naloxone access provisions, generally; Naloxone access provisions in S.3158, Labor/HHS appropriations bill
Foreign entity interest: Adapt Pharma is a U.S. domestic subsidiary of a foreign parent. All lobbying efforts, while not controlled, supervised, or directed by the parent, benefit the parent tangentially.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBORAH LYNN BURRELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.